Edinburgh Research Explorer

Kynurenine 3-monooxygenase is a critical regulator of renal ischemia–reperfusion injury

Research output: Contribution to journalArticle

Original languageEnglish
Article number15
JournalExperimental and Molecular Medicine
Volume51
Early online date13 Feb 2019
DOIs
Publication statusE-pub ahead of print - 13 Feb 2019

Abstract

Acute kidney injury (AKI) following ischemia-reperfusion injury (IRI) has a high mortality and lacks specific therapies. Here, we report that mice lacking kynurenine 3-monooxygenase (KMO) activity (Kmonull mice) are protected against AKI after renal IRI. We show that KMO is highly expressed in the kidney and exerts major metabolic control over the biologically-active kynurenine metabolites 3-hydroxykynurenine, kynurenic acid and downstream metabolites. In experimental AKI induced by kidney IRI, Kmonull mice had preserved renal function, reduced renal tubular cell injury, and fewer infiltrating neutrophils compared to wild-type (Kmowt) control mice. Together, these data confirm that flux through KMO contributes to AKI after IRI, and supports the rationale for KMO inhibition as a therapeutic strategy to protect against AKI during critical illness.

Download statistics

No data available

ID: 77462428